Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii

Standard therapy (isoniazid, rifampin, and ethambutol), with or without a macrolide, for pulmonary Mycobacterium kansasii lasts more than a year. Therefore, shorter treatment duration regimens are required. We used data from 32 Taiwanese patients treated with standard therapy who were followed using...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Autores principales: Srivastava, Shashikant, Wang, Jann-Yuan, Magombedze, Gesham, Chapagain, Moti, Huang, Hung-Ling, Deshpande, Devyani, Heysell, Scott K., Pasipanodya, Jotam G., Gumbo, Tawanda
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2021
Materias:
Pharmacology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8092872/
https://ncbi.nlm.nih.gov/pubmed/33558291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01553-20
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares